European access discussions shouldn’t stop at reimbursement (Guest blog)

In Europe, a new wave of scientific innovation is generating an unparalleled level of choice and promise in cancer treatments. Yet, most cancer patients in Europe tend to have longer waiting times than needed to access a new cancer treatment. Even after reimbursement, patient access varies tremendously from country to country. In this blog we argue why it’s vital to start discussing access beyond market access.

Read the full blog here.

Bas Amesz

Bas Amesz is a Partner at Vintura.
Read Morechevron_right